{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:08:39Z","timestamp":1793315319050,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called \u201ccytokine storm\u201d, clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages.<\/jats:p>","DOI":"10.1038\/s41392-020-0191-1","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:03:32Z","timestamp":1590710612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":487,"title":["Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2"],"prefix":"10.1038","volume":"5","author":[{"given":"Michele","family":"Catanzaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fagiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Racchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-6837","authenticated-orcid":false,"given":"Stefano","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3061-4738","authenticated-orcid":false,"given":"Cristina","family":"Lanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"191_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565\u2013574 (2020).","journal-title":"Lancet"},{"key":"191_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s00108-019-00671-5","volume":"60","author":"VM Corman","year":"2019","unstructured":"Corman, V. M., Lienau, J. & Witzenrath, M. Coronaviruses as the cause of respiratory infections. Internist 60, 1136\u20131145 (2019).","journal-title":"Internist"},{"key":"191_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1128\/CMR.00102-14","volume":"28","author":"JFW Chan","year":"2015","unstructured":"Chan, J. F. W. et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin. Microbiol. Rev. 28, 465\u2013522 (2015).","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"191_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1071\/MA20013","volume":"41","author":"John S Mackenzie","year":"2020","unstructured":"Mackenzie, J. S. & Smith, D. W. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don\u2019t. Microbiol. Aust. https:\/\/doi.org\/10.1071\/MA20013 (2020).","journal-title":"Microbiology Australia"},{"key":"191_CR5","doi-asserted-by":"publisher","first-page":"14040","DOI":"10.1073\/pnas.0506735102","volume":"102","author":"SKP Lau","year":"2005","unstructured":"Lau, S. K. P. et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl Acad. Sci. U. S. A. 102, 14040\u201314045 (2005).","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"191_CR6","first-page":"E028","volume":"43","author":"L Zhou","year":"2020","unstructured":"Zhou, L., Liu, K. & Liu, H. G. Cause analysis and treatment strategies of recurrence' with novel coronavirus pneumonia (covid-19) patients after discharge from hospital. Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin. J. Tuberc. Respir. Dis. 43, E028 (2020).","journal-title":"J. Tuberc. Respir. Dis."},{"key":"191_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","volume":"9","author":"JF-W Chan","year":"2020","unstructured":"Chan, J. F.-W. et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 9, 221\u2013236 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"191_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"191_CR9","doi-asserted-by":"publisher","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94, e00127-20 (2020).","journal-title":"J. Virol."},{"key":"191_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).","journal-title":"Nat. Commun."},{"key":"191_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/path.1560","volume":"203","author":"Y Ding","year":"2004","unstructured":"Ding, Y. et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J. Pathol. 203, 622\u2013630 (2004).","journal-title":"J. Pathol."},{"key":"191_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1084\/jem.20050828","volume":"202","author":"J Gu","year":"2005","unstructured":"Gu, J. et al. Multiple organ infection and the pathogenesis of SARS. J. Exp. Med. 202, 415\u2013424 (2005).","journal-title":"J. Exp. Med."},{"key":"191_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203, 631\u2013637 (2004).","journal-title":"J. Pathol."},{"key":"191_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41368-020-0074-x","volume":"12","author":"H Xu","year":"2020","unstructured":"Xu, H. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral. Sci. 12, 8 (2020).","journal-title":"Int. J. Oral. Sci."},{"key":"191_CR15","first-page":"26.919985","volume":"2020","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Biorxiv 2020, 26.919985 (2020).","journal-title":"Biorxiv"},{"key":"191_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond. Engl. 395, 497\u2013506 (2020).","journal-title":"Lancet Lond. Engl."},{"key":"191_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420\u2013422 (2020).","journal-title":"Lancet Respir. Med."},{"key":"191_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"191_CR19","doi-asserted-by":"publisher","unstructured":"Shi, Y. et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. medRxiv https:\/\/doi.org\/10.1101\/2020.03.12.20034736 (2020).","DOI":"10.1101\/2020.03.12.20034736"},{"key":"191_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","author":"C Qin","year":"2020","unstructured":"Qin, C. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am. https:\/\/doi.org\/10.1093\/cid\/ciaa248 (2020).","journal-title":"Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am."},{"key":"191_CR21","doi-asserted-by":"publisher","unstructured":"Zhang, B. et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. https:\/\/doi.org\/10.1101\/2020.03.12.20035048. (2020).","DOI":"10.1101\/2020.03.12.20035048"},{"key":"191_CR22","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034 (2020).","journal-title":"Lancet"},{"key":"191_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-020-0163-5","volume":"5","author":"D Li","year":"2020","unstructured":"Li, D. et al. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study. Signal Transduct. Target. Ther. 5, 62 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"191_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nri1732","volume":"5","author":"S Perlman","year":"2005","unstructured":"Perlman, S. & Dandekar, A. A. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 5, 917\u2013927 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"191_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1099\/jgv.0.000351","volume":"97","author":"J Tynell","year":"2016","unstructured":"Tynell, J. et al. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J. Gen. Virol. 97, 344\u2013355 (2016).","journal-title":"J. Gen. Virol."},{"key":"191_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/infdis\/jit504","volume":"209","author":"J Zhou","year":"2014","unstructured":"Zhou, J. et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J. Infect. Dis. 209, 1331\u20131342 (2014).","journal-title":"J. Infect. Dis."},{"key":"191_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"191_CR28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijid.2020.03.003","volume":"93","author":"D Chen","year":"2020","unstructured":"Chen, D. et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. Int. J. Infect. Dis. IJID . Publ. Int. Soc. Infect. Dis. 93, 297\u2013299 (2020).","journal-title":"J. Infect. Dis. IJID . Publ. Int. Soc. Infect. Dis."},{"key":"191_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","volume":"5","author":"L Tan","year":"2020","unstructured":"Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct. Target. Ther. 5, 33 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"191_CR30","doi-asserted-by":"publisher","unstructured":"Wen, W. et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. medRxiv https:\/\/doi.org\/10.1101\/2020.03.23.20039362 (2020).","DOI":"10.1101\/2020.03.23.20039362"},{"key":"191_CR31","doi-asserted-by":"publisher","unstructured":"Long, Q.-X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-0897-1 (2020).","DOI":"10.1038\/s41591-020-0897-1"},{"key":"191_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0167-5699(00)01699-6","volume":"21","author":"A Alcami","year":"2000","unstructured":"Alcami, A. & Koszinowski, U. H. Viral mechanisms of immune evasion. Immunol. Today 21, 447\u2013455 (2000).","journal-title":"Immunol. Today"},{"key":"191_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523\u2013534 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"191_CR34","doi-asserted-by":"publisher","unstructured":"Wan, S. et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv https:\/\/doi.org\/10.1101\/2020.02.10.20021832 (2020).","DOI":"10.1101\/2020.02.10.20021832"},{"key":"191_CR35","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl. Sci. Rev. https:\/\/doi.org\/10.1093\/nsr\/nwaa037 (2020).","DOI":"10.1093\/nsr\/nwaa037"},{"key":"191_CR36","doi-asserted-by":"publisher","first-page":"102523","DOI":"10.1016\/j.autrev.2020.102523","volume":"19","author":"EG Favalli","year":"2020","unstructured":"Favalli, E. G. et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun. Rev. 19, 102523 (2020).","journal-title":"Autoimmun. Rev."},{"key":"191_CR37","doi-asserted-by":"publisher","unstructured":"Gou, W. et al. Gut microbiota may underlie the predisposition of healthy individuals to COVID-19. medRxiv https:\/\/doi.org\/10.1101\/2020.04.22.20076091 (2020).","DOI":"10.1101\/2020.04.22.20076091"},{"key":"191_CR38","doi-asserted-by":"publisher","first-page":"eaaw1347","DOI":"10.1126\/scisignal.aaw1347","volume":"12","author":"M de Marcken","year":"2019","unstructured":"de Marcken, M., Dhaliwal, K., Danielsen, A. C., Gautron, A. S. & Dominguez-Villar, M. TLR7 and TLR8 activate distinct pathways in monocytes during RNA virus infection. Sci. Signal 12, eaaw1347 (2019).","journal-title":"Sci. Signal"},{"key":"191_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007390","volume":"14","author":"J Olejnik","year":"2018","unstructured":"Olejnik, J., Hume, A. J. & M\u00fchlberger, E. Toll-like receptor 4 in acute viral infection: Too much of a good thing. PLoS Pathog. 14, e1007390 (2018).","journal-title":"PLoS Pathog."},{"key":"191_CR40","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.cell.2011.08.015","volume":"146","author":"JR Teijaro","year":"2011","unstructured":"Teijaro, J. R. et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146, 980\u2013991 (2011).","journal-title":"Cell"},{"key":"191_CR41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nri910","volume":"2","author":"Q Li","year":"2002","unstructured":"Li, Q. & Verma, I. M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2, 725\u2013734 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"191_CR42","doi-asserted-by":"publisher","first-page":"6758","DOI":"10.1038\/sj.onc.1209943","volume":"25","author":"MS Hayden","year":"2006","unstructured":"Hayden, M. S., West, A. P. & Ghosh, S. NF-\u03baB and the immune response. Oncogene 25, 6758\u20136780 (2006).","journal-title":"Oncogene"},{"key":"191_CR43","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1128\/JVI.02576-13","volume":"88","author":"ML DeDiego","year":"2014","unstructured":"DeDiego, M. L. et al. Inhibition of NF-\u03baB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J. Virol. 88, 913 (2014).","journal-title":"J. Virol."},{"key":"191_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000756","volume":"6","author":"SL Smits","year":"2010","unstructured":"Smits, S. L. et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 6, e1000756 (2010).","journal-title":"PLoS Pathog."},{"key":"191_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2007.02.007","volume":"128","author":"W Wang","year":"2007","unstructured":"Wang, W. et al. Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res. 128, 1\u20138 (2007).","journal-title":"Virus Res."},{"key":"191_CR46","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1038\/sj.onc.1209941","volume":"25","author":"J Hiscott","year":"2006","unstructured":"Hiscott, J., Nguyen, T.-L. A., Arguello, M., Nakhaei, P. & Paz, S. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 25, 6844\u20136867 (2006).","journal-title":"Oncogene"},{"key":"191_CR47","doi-asserted-by":"publisher","first-page":"iv70","DOI":"10.1136\/ard.2003.015263","volume":"64","author":"J Clark","year":"2005","unstructured":"Clark, J., Vagenas, P., Panesar, M. & Cope, A. P. What does tumour necrosis factor excess do to the immune system long term? Ann. Rheum. Dis. 64, iv70\u2013iv76 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"191_CR48","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2217\/imt.10.67","volume":"2","author":"LCR Silva","year":"2010","unstructured":"Silva, L. C. R., Ortigosa, L. C. M. & Benard, G. Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2, 817\u2013833 (2010).","journal-title":"Immunotherapy"},{"key":"191_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/03946320140270S103","volume":"27","author":"G Lapadula","year":"2014","unstructured":"Lapadula, G. et al. Adalimumab in the treatment of immune-mediated diseases. Int. J. Immunopathol. Pharmacol. 27, 33\u201348 (2014).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"191_CR50","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"P Charles","year":"1999","unstructured":"Charles, P. et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163, 1521\u20131528 (1999).","journal-title":"J. Immunol."},{"key":"191_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","volume":"19","author":"M Feldmann","year":"2001","unstructured":"Feldmann, M. & Maini, R. N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163\u2013196 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"191_CR52","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak, H. F., Brown, L. F., Detmar, M. & Dvorak, A. M. Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029\u20131039 (1995).","journal-title":"Am. J. Pathol."},{"key":"191_CR53","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1073\/pnas.0711241105","volume":"105","author":"S Haga","year":"2008","unstructured":"Haga, S. et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc. Natl Acad. Sci. USA 105, 7809\u20137814 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"191_CR54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway, J. B. et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 50, 124\u2013131 (2011).","journal-title":"Rheumatology."},{"key":"191_CR55","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1006\/jsre.1996.0120","volume":"61","author":"T Hirano","year":"1996","unstructured":"Hirano, T. Pancreatic injuries in rats with fecal peritonitis: protective effect of a new synthetic protease inhibitor, sepinostat mesilate (FUT-187). J. Surg. Res. 61, 301\u2013306 (1996).","journal-title":"J. Surg. Res."},{"key":"191_CR56","doi-asserted-by":"publisher","first-page":"458","DOI":"10.5414\/CNP59458","volume":"59","author":"H Takahashi","year":"2003","unstructured":"Takahashi, H. et al. Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient. Clin. Nephrol. 59, 458\u2013462 (2003).","journal-title":"Clin. Nephrol."},{"key":"191_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.antiviral.2011.07.014","volume":"92","author":"OP Zhirnov","year":"2011","unstructured":"Zhirnov, O. P., Klenk, H. D. & Wright, P. F. Aprotinin and similar protease inhibitors as drugs against influenza. Antivir. Res. 92, 27\u201336 (2011).","journal-title":"Antivir. Res."},{"key":"191_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pupt.2015.07.001","volume":"33","author":"M Yamaya","year":"2015","unstructured":"Yamaya, M. et al. The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells. Pulm. Pharmacol. Ther. 33, 66\u201374 (2015).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"191_CR59","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1254\/jphs.08162FP","volume":"108","author":"M Ishizaki","year":"2008","unstructured":"Ishizaki, M. et al. Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma. J. Pharmacol. Sci. 108, 355\u2013363 (2008).","journal-title":"J. Pharmacol. Sci."},{"key":"191_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48577-4","volume":"9","author":"AC Florencio","year":"2019","unstructured":"Florencio, A. C. et al. Effects of the serine protease inhibitor rBmTI-A in an experimental mouse model of chronic allergic pulmonary inflammation. Sci. Rep. 9, 12624 (2019).","journal-title":"Sci. Rep."},{"key":"191_CR61","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaci.2006.02.047","volume":"118","author":"C-L Chen","year":"2006","unstructured":"Chen, C.-L. et al. Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J. Allergy Clin. Immunol. 118, 105\u2013112 (2006).","journal-title":"J. Allergy Clin. Immunol."},{"key":"191_CR62","first-page":"879326","volume":"2014","author":"C-C Lin","year":"2014","unstructured":"Lin, C.-C. et al. The effect of serine protease inhibitors on airway inflammation in a chronic allergen-induced asthma mouse model. Mediators Inflamm. 2014, 879326 (2014).","journal-title":"Mediators Inflamm."},{"key":"191_CR63","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/jpet.102.041988","volume":"305","author":"M Yuksel","year":"2003","unstructured":"Yuksel, M., Okajima, K., Uchiba, M. & Okabe, H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J. Pharmacol. Exp. Ther. 305, 298\u2013305 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"191_CR64","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"Chi Zhang","year":"2020","unstructured":"Zhang, C., Wu, Z., Li, J.-W., Zhao, H. & Wang, G.-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105954 (2020).","journal-title":"International Journal of Antimicrobial Agents"},{"key":"191_CR65","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1124\/mol.105.018481","volume":"69","author":"C Lee","year":"2006","unstructured":"Lee, C. et al. Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production. Mol. Pharmacol. 69, 1041\u20131047 (2006).","journal-title":"Mol. Pharmacol."},{"key":"191_CR66","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13098-017-0266-5","volume":"9","author":"MV Wainstein","year":"2017","unstructured":"Wainstein, M. V. et al. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. Diabetol. Metab. Syndr. 9, 67 (2017).","journal-title":"Diabetol. Metab. Syndr."},{"key":"191_CR67","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/08820139.2018.1480034","volume":"47","author":"B Zhang","year":"2018","unstructured":"Zhang, B., Li, X.-L., Zhao, C.-R., Pan, C.-L. & Zhang, Z. Interleukin-6 as a predictor of the risk of cardiovascular disease: a meta-analysis of prospective epidemiological studies. Immunol. Invest. 47, 689\u2013699 (2018).","journal-title":"Immunol. Invest."},{"key":"191_CR68","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1182\/blood.V91.1.258","volume":"91","author":"P Biswas","year":"1998","unstructured":"Biswas, P. et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 91, 258\u2013265 (1998).","journal-title":"Blood"},{"key":"191_CR69","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.4049\/jimmunol.172.9.5676","volume":"172","author":"RM McLoughlin","year":"2004","unstructured":"McLoughlin, R. M. et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J. Immunol. 172, 5676 (2004).","journal-title":"J. Immunol."},{"key":"191_CR70","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/01.ATV.0000016249.96529.B8","volume":"22","author":"M van der Meer Irene","year":"2002","unstructured":"van der Meer Irene, M. et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22, 838\u2013842 (2002).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"191_CR71","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s11596-013-1168-x","volume":"33","author":"S Xiang","year":"2013","unstructured":"Xiang, S. et al. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6\/IFN-\u03b3-induced vascular smooth muscle cells. J. Huazhong Univ. Sci. Technol. Med. Sci. Hua Zhong Ke Ji Xue Xue Bao Yi Xue Ying Wen Ban. Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban. 33, 615\u2013622 (2013).","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci. Hua Zhong Ke Ji Xue Xue Bao Yi Xue Ying Wen Ban. Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban."},{"key":"191_CR72","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1111\/bph.12713","volume":"171","author":"D Qu","year":"2014","unstructured":"Qu, D., Liu, J., Lau, C. W. & Huang, Y. IL-6 in diabetes and cardiovascular complications. Br. J. Pharmacol. 171, 3595\u20133603 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"191_CR73","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1161\/01.RES.87.12.1195","volume":"87","author":"B Schieffer","year":"2000","unstructured":"Schieffer, B. et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK\/STAT signaling and cytokine induction. Circ. Res. 87, 1195\u20131201 (2000).","journal-title":"Circ. Res."},{"key":"191_CR74","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/375247a0","volume":"375","author":"MB Marrero","year":"1995","unstructured":"Marrero, M. B. et al. Direct stimulation of Jak\/STAT pathway by the angiotensin II AT1 receptor. Nature 375, 247\u2013250 (1995).","journal-title":"Nature"},{"key":"191_CR75","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875\u2013879 (2005).","journal-title":"Nat. Med."},{"key":"191_CR76","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1128\/JVI.01248-09","volume":"84","author":"I Glowacka","year":"2010","unstructured":"Glowacka, I. et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol. 84, 1198\u20131205 (2010).","journal-title":"J. Virol."},{"key":"191_CR77","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1161\/HYPERTENSIONAHA.118.10266","volume":"71","author":"S Eguchi","year":"2018","unstructured":"Eguchi, S., Kawai, T., Scalia, R. & Rizzo, V. Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology. Hypertension 71, 804\u2013810 (2018).","journal-title":"Hypertension"},{"key":"191_CR78","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","volume":"50","author":"M Murakami","year":"2019","unstructured":"Murakami, M., Kamimura, D. & Hirano, T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity 50, 812\u2013831 (2019).","journal-title":"Immunity"},{"issue":"5","key":"191_CR79","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"52","author":"Toshio Hirano","year":"2020","unstructured":"Hirano, T. & Murakami, M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2020.04.003 (2020).","journal-title":"Immunity"},{"key":"191_CR80","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","volume":"20","author":"J Stebbing","year":"2020","unstructured":"Stebbing, J. et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis. 20, 400\u2013402 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"191_CR81","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1172\/JCI89857","volume":"127","author":"E Bekerman","year":"2017","unstructured":"Bekerman, E. et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J. Clin. Invest. 127, 1338\u20131352 (2017).","journal-title":"J. Clin. Invest."},{"key":"191_CR82","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.antiviral.2018.05.001","volume":"155","author":"S-Y Pu","year":"2018","unstructured":"Pu, S.-Y. et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antivir. Res. 155, 67\u201375 (2018).","journal-title":"Antivir. Res."},{"key":"191_CR83","doi-asserted-by":"publisher","unstructured":"Gurwitz, D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev. Res. https:\/\/doi.org\/10.1002\/ddr.21656 (2020).","DOI":"10.1002\/ddr.21656"},{"key":"191_CR84","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41569-020-0360-5","volume":"17","author":"Y-Y Zheng","year":"2020","unstructured":"Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y. & Xie, X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 17, 259\u2013260 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"191_CR85","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez, G. A. M. et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J. Clin. Invest. 128, 3041\u20133052 (2018).","journal-title":"J. Clin. Invest."},{"key":"191_CR86","first-page":"401","volume":"24","author":"FJ Sorrell","year":"2016","unstructured":"Sorrell, F. J., Szklarz, M., Abdul Azeez, K. R., Elkins, J. M. & Knapp, S. Family-wide structural analysis of human numb-associated protein kinases. Struct. Lond. Engl. 1993 24, 401\u2013411 (2016).","journal-title":"Struct. Lond. Engl. 1993"},{"key":"191_CR87","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.3390\/vaccines4030023","volume":"4","author":"SB Fleming","year":"2016","unstructured":"Fleming, S. B. Viral inhibition of the IFN-induced JAK\/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists. Vaccines 4, E23 (2016).","journal-title":"Vaccines"},{"key":"191_CR88","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nri2974","volume":"11","author":"S Spiegel","year":"2011","unstructured":"Spiegel, S. & Milstien, S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat. Rev. Immunol. 11, 403\u2013415 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"191_CR89","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12836","volume":"20","author":"AM Bryan","year":"2018","unstructured":"Bryan, A. M. & Del Poeta, M. Sphingosine-1-phosphate receptors and innate immunity. Cell. Microbiol. 20, e12836 (2018).","journal-title":"Cell. Microbiol."},{"key":"191_CR90","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1073\/pnas.1400593111","volume":"111","author":"JR Teijaro","year":"2014","unstructured":"Teijaro, J. R., Walsh, K. B., Rice, S., Rosen, H. & Oldstone, M. B. A. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc. Natl Acad. Sci. USA 111, 3799\u20133804 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"191_CR91","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat, F. & Krammer, F. SARS-CoV-2 Vaccines: Status Report. Immunity 52, 583\u2013589 (2020).","journal-title":"Immunity"},{"key":"191_CR92","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1128\/JVI.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201\u201312215 (2011).","journal-title":"J. Virol."},{"key":"191_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"C-T Tseng","year":"2012","unstructured":"Tseng, C.-T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).","journal-title":"PLoS ONE"},{"key":"191_CR94","doi-asserted-by":"publisher","unstructured":"Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity https:\/\/doi.org\/10.1016\/j.immuni.2020.04.023 (2020).","DOI":"10.1016\/j.immuni.2020.04.023"},{"key":"191_CR95","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue, M. L. et al. First Case of 2019 Novel Coronavirus in the United States. N. Engl. J. Med. 382, 929\u2013936 (2020).","journal-title":"N. Engl. J. Med."},{"key":"191_CR96","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e79","volume":"35","author":"J Lim","year":"2020","unstructured":"Lim, J. et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J. Korean Med. Sci. 35, e79 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"191_CR97","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","volume":"57","author":"Andrea Cortegiani","year":"2020","unstructured":"Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A. & Einav, S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care https:\/\/doi.org\/10.1016\/j.jcrc.2020.03.005 (2020).","journal-title":"Journal of Critical Care"},{"key":"191_CR98","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrneph.2011.150","volume":"7","author":"S-J Lee","year":"2011","unstructured":"Lee, S.-J., Silverman, E. & Bargman, J. M. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat. Rev. Nephrol. 7, 718\u2013729 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"191_CR99","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","volume":"177","author":"F Touret","year":"2020","unstructured":"Touret, F. & de Lamballerie, X. Of chloroquine and COVID-19. Antivir. Res. 177, 104762 (2020).","journal-title":"Antivir. Res."},{"key":"191_CR100","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/444461","volume":"41","author":"J Xu","year":"2005","unstructured":"Xu, J. et al. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin. Infect. Dis. 41, 1089\u20131096 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"191_CR101","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.1128\/JVI.00737-08","volume":"82","author":"J Netland","year":"2008","unstructured":"Netland, J., Meyerholz, D. K., Moore, S., Cassell, M. & Perlman, S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 82, 7264\u20137275 (2008).","journal-title":"J. Virol."},{"key":"191_CR102","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/infdis\/jiv499","volume":"213","author":"K Li","year":"2016","unstructured":"Li, K. et al. Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J. Infect. Dis. 213, 712\u2013722 (2016).","journal-title":"J. Infect. Dis."},{"issue":"6","key":"191_CR103","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/jmv.25728","volume":"92","author":"Yan\u2010Chao Li","year":"2020","unstructured":"Li, Y.-C., Bai, W.-Z. & Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.25728 (2020).","journal-title":"Journal of Medical Virology"},{"key":"191_CR104","doi-asserted-by":"publisher","unstructured":"Mao, L. et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv https:\/\/doi.org\/10.1101\/2020.02.22.20026500 (2020).","DOI":"10.1101\/2020.02.22.20026500"},{"key":"191_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09536-z","volume":"7","author":"Q Wu","year":"2017","unstructured":"Wu, Q. et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci. Rep. 7, 9110 (2017).","journal-title":"Sci. Rep."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0191-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0191-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0191-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T13:07:13Z","timestamp":1696165633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-0191-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["191"],"URL":"https:\/\/doi.org\/10.1038\/s41392-020-0191-1","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}